SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 24,100 shares, a growth of 66.2% from the October 15th total of 14,500 shares. Based on an average daily trading volume, of 43,100 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. raised its holdings in SOPHiA GENETICS by 5.0% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock worth $1,002,000 after buying an additional 9,700 shares during the period. Akre Capital Management LLC bought a new position in SOPHiA GENETICS during the first quarter worth $1,418,000. Principal Financial Group Inc. lifted its position in SOPHiA GENETICS by 35.9% during the second quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after acquiring an additional 361,201 shares during the last quarter. Banque Cantonale Vaudoise lifted its holdings in shares of SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after buying an additional 9,000 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares during the period. 31.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on SOPH. Morgan Stanley downgraded SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $10.00 to $5.00 in a report on Wednesday, August 7th. Royal Bank of Canada lowered their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th.

SOPHiA GENETICS Trading Down 7.3 %

Shares of SOPH stock traded down $0.29 on Wednesday, reaching $3.70. 7,141 shares of the stock were exchanged, compared to its average volume of 67,266. The stock has a 50 day moving average price of $3.66 and a 200 day moving average price of $4.19. The stock has a market cap of $241.91 million, a PE ratio of -3.41 and a beta of 1.03. SOPHiA GENETICS has a one year low of $2.70 and a one year high of $7.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. During the same period last year, the firm earned ($0.21) earnings per share. Equities research analysts forecast that SOPHiA GENETICS will post -0.95 EPS for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.